Tom Soloway is the founder of T-knife. T-knife has raised $110M in total funding. Latest round: Series B. Based in San Francisco, United States.
Thomas M. Soloway is the Chief Executive Officer of T-knife Therapeutics, Inc., a company focused on developing next-generation T-cell receptor (TCR) therapies for solid tumor patients. T-knife secured $110 million in Series B financing to expand its scientific team, increase manufacturing capacity, and advance its pipeline of TCR-engineered T cell therapies. The company is progressing its lead program, TK-8001, toward clinical studies.
Full founder directory · Investor directory · Company funding database · Fundraising library